SPI1 Mediates N-Myristoyltransferase 1 to Advance Gastric Cancer Progression via PI3K/AKT/mTOR Pathway

Figure 4

SPI1-targeted NMT1. (a, b) The binding sites between SPI1 and NMT1 were predicted by JASPAR database (https://jaspar.genereg.net/). (c, d) The enrichment of NMT1 in the anti-IgG and anti-SPI1 groups of AGS (c) and SNU-5 (d) cells was determined by chromatin immunoprecipitation assay. (e) Luciferase reporter assay was applied to determine the binding between SPI1 and NMT1. ^∗∗∗ < 0.001 vs. NC group; ^∧∧∧ < 0.001 vs. anti-IgG. All experiments were repeated independently at least three times. Data were performed as the means ± standard deviation. NMT1, N-myristoyltransferase 1; NMT1-WT, wild-type NMT1; NMT1-MUT, mutative NMT1; NC, negative control.

(a)

(b)

(c)

(d)

(e)